MCL Literature Feed
41 papers on mantle cell lymphoma from PubMed. Updated daily.
Genomic analysis reveals MCL relapse is driven by the expansion of pre-existing resistant subclones, not new mutations, highlighting the need for deep sequencing at diagnosis to prevent recurrence.
This comprehensive review synthesizes emerging biomarkers beyond standard prognosticators, including MRD, ctDNA, and advanced imaging, to better guide personalized treatment in the targeted therapy era.
A novel single-cell technique, LiP-Seq, identified IFITM2 upregulation in rare persistent MCL cells post-CAR-T, revealing a new mechanism of immune evasion and a potential therapeutic target.
Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.
A novel liquid biopsy technique using cell-free chromatin profiling non-invasively tracks disease origin and monitors therapy response, offering a powerful new tool for MRD and biomarker discovery.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Undetectable MRD after induction chemotherapy identifies mantle cell lymphoma patients who may safely omit consolidative autologous stem cell transplant, enabling a personalized, de-escalation treatment strategy.
This phase 2 study of frontline acalabrutinib, lenalidomide, and anti-CD20 demonstrates high molecular response rates (67-90%) and 76% 4-year PFS, supporting a time-limited, MRD-driven, chemotherapy-free treatment strategy.
Long-term follow-up (37.2 months) in Japanese relapsed/refractory MCL patients shows the ibrutinib-venetoclax combination yields durable complete responses (83% CR), high MRD negativity, and a manageable safety profile.
The EHA-EU MCL network published comprehensive guidelines standardizing risk-stratified diagnosis and treatment for MCL, covering young/fit and elderly patients in both frontline and relapsed/refractory settings.
High-throughput sequencing accurately identifies IGHV somatic hypermutation status, a key prognostic biomarker in MCL, even in complex, multi-clonal samples, improving risk stratification and MRD tracking.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
ctDNA sequencing in relapsed/refractory MCL identifies SMARCA4 and TP53 mutations as response predictors and offers more sensitive MRD monitoring than qPCR, improving non-invasive risk stratification.
Comprehensive cfDNA analysis non-invasively tracks MCL disease burden and detects high-risk mutations, offering a powerful liquid biopsy tool for monitoring and risk stratification.
This review summarizes the integration of BTK inhibitors into frontline MCL therapy and the emerging role of MRD, providing a treatment algorithm for managing newly diagnosed patients.
This phase II trial protocol compares chemo-free ibrutinib/venetoclax/rituximab versus ibrutinib-chemoimmunotherapy in treatment-naive elderly MCL, aiming to establish a new frontline standard.
The Japanese Society of Hematology's 2023 guidelines provide updated, evidence-based recommendations on risk stratification and treatment algorithms for managing mantle cell lymphoma in clinical practice.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This review summarizes current MCL risk stratification (MIPI, TP53), highlights emerging genomic biomarkers, and emphasizes MRD monitoring as a key dynamic tool for personalizing therapy, especially for high-risk patients.
In frontline MCL, pre-treatment ctDNA levels and TP53 mutations predict poor survival, while post-treatment ctDNA clearance identifies patients with favorable outcomes, establishing its clinical utility for prognosis.
The chemotherapy-free triplet of acalabrutinib (BTKi), umbralisib (PI3Ki), and ublituximab (anti-CD20) achieved high response and MRD-negativity rates in untreated MCL, presenting a novel frontline option.
Alternating R-DA-EDOCH/R-DHAP induction for young, newly diagnosed MCL patients achieved an 89% complete remission rate and high MRD negativity, offering a potent new frontline intensive chemotherapy option.
In previously untreated, transplant-ineligible MCL, achieving MRD-negativity after bendamustine-obinutuzumab induction allows for the safe omission of maintenance therapy without worsening progression-free survival.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This review summarizes how BTKi integration into frontline therapy (TRIANGLE trial) challenges the role of transplant, while CAR-T cells are established as the best option after BTKi failure.
In mantle cell lymphoma, MRD assessment is most predictive of survival after four induction cycles, while rapid clearance within two cycles offers no prognostic benefit, guiding risk stratification.
This comprehensive review outlines evolving frontline MCL strategies, highlighting the integration of targeted agents, re-evaluation of transplant, and the emerging role of MRD-guided therapy to improve outcomes.
This review advocates for using prognostic tools like MIPI and TP53 status to guide risk-adapted therapy in MCL, intensifying for high-risk and de-escalating for low-risk patients.
The chemotherapy-free BOVen regimen (zanubrutinib, obinutuzumab, venetoclax) shows high efficacy (88% CR) and deep MRD negativity in previously untreated, high-risk TP53-mutated MCL, a historically chemo-refractory population.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
This methods paper details using sensitive qPCR and ddPCR to detect MRD in B-cell lymphomas by targeting Ig gene rearrangements and chromosomal translocations, relevant for MCL's t(11;14).
Italian experts established consensus diagnostic and therapeutic pathways for MCL, standardizing care while highlighting ongoing debates on MRD utility, immunotherapy sequencing, and CAR-T versus bispecifics.
Reviewing AIM and SYMPATICO trials, the ibrutinib-venetoclax combination shows high efficacy in relapsed/refractory MCL, supporting a potential fixed-duration, MRD-guided treatment strategy.
This review confirms MRD's strong prognostic value in MCL but cautions that technical limitations and the uncertain clinical significance of low-level disease currently prevent its routine use for treatment decisions.
The VALERIA trial demonstrates that an MRD-guided, fixed-duration venetoclax-lenalidomide-rituximab regimen is a highly effective, personalized, chemotherapy-free strategy for patients with relapsed/refractory MCL.